Alternative Data for Geron
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 9 | Sign up | Sign up | Sign up |
| Sentiment | 94 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Employee Rating | 54 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 40 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 21,394 | Sign up | Sign up | Sign up |
| X Mentions | 25 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 20 | Sign up | Sign up | Sign up |
| Linkedin Employees | 397 | Sign up | Sign up | Sign up |
About Geron
Geron Corporation is a biotechnology company located in Foster City, California, which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
| Price | $1.63 |
| Target Price | Sign up |
| Volume | 13,291,106 |
| Market Cap | $977M |
| Year Range | $1.07 - $1.95 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Geron Corporation Q4 2025 Earnings Call SummaryFebruary 25 - Moby.co |
|
Geron Q4 Earnings Call HighlightsFebruary 25 - MarketBeat |
|
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsFebruary 25 - GlobeNewswire |
|
 |
Geron Corp (NASDAQ:GERN) Stock Plummets 10% After Q4 Revenue MissFebruary 24 - ChartMill |
 |
Earnings Summary: Geron Q4February 24 - Benzinga |
Geron Q4 EPS $(0.05) Misses $(0.03) Estimate, Sales $48.015M Miss $50.420M EstimateFebruary 24 - Benzinga |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 47M | 22M | 25M | -18M | -9.7M | -0.030 |
| Q2 '25 | 49M | 1.2M | 48M | -16M | -7.6M | -0.020 |
| Q1 '25 | 40M | 1.2M | 38M | -20M | -11M | -0.030 |
| Q4 '24 | 48M | 780,000 | 47M | -25M | -16M | -0.036 |
| Q3 '24 | 28M | 460,000 | 28M | -26M | -23M | -0.040 |
Insider Transactions View All
| ROBERTSON MICHELLE filed to sell 17,645 shares at $1.9. February 19 '26 |
| LAWLIS V BRYAN filed to buy 13,300 shares at $1.2. May 13 '25 |
| SCARLETT JOHN A filed to buy 12,500 shares at $1.8. March 3 '25 |
| Samuels Scott Alan filed to buy 26,682 shares at $1.6. March 3 '25 |
| Ziegler James filed to buy 100,000 shares at $1.6. March 3 '25 |
Similar companies
Read more about Geron (GERN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Geron
The Market Cap of Geron is $977M.
Currently, the price of one share of Geron stock is $1.63.
The GERN stock price chart above provides a comprehensive visual representation of Geron's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Geron shares. Our platform offers an up-to-date GERN stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Geron (GERN) does not offer dividends to its shareholders. Investors interested in Geron should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Geron are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
